A case series from a phase II basket trial including one patient with recurrent squamous vulvar carcinoma and prior progression to systemic carboplatin showed a 30% reduction in PD-L1 positive tumor lesions following pembrolizumab [81]. This evidence concerns the gene CD274 and neoplasm.